GE End-tidal Control

History

2022: GE Healthcare Released Automatic Anesthesia Injection Software

On April 4, 2022, GE Healthcare announced the launch of End-tidal (Et) Control software to perform general anesthesia on the Aisys CS2 anesthesia delivery system. The company is the only manufacturer that has received approval to use a general anesthesia system with late tide concentration control in the United States.

Anesthesiologists use the ON () Et Control software to care for patients in more than 100 countries. Every year, more than 300 million patients worldwide undergo surgical operations, many of which require general anesthesia using inhalation anesthetics, which costs $1.2 billion annually. Et Control semi-automates the anesthesia with software, allowing anesthesiologists to set target values for the final concentration of oxygen and anesthetic. After setting goals, the software quickly achieves and maintains established goals, regardless of changes in the hemodynamic and metabolic status of the patient. Et Control improves the accuracy of anesthesia and simplifies the working process, while reducing drug waste, as well as reducing the cost of treatment.

GE Healthcare Released Automatic Anesthesia Injection Software

Compared to a manual process, Et Control software, according to developers, can offer the following advantages:

• A potential 44% reduction in greenhouse gas emissions through more efficient use of anesthetic agents;
• Improved accuracy of maintaining target concentrations of oxygen and anesthetic agents;
• A 50% reduction in manual keystrokes, which helps physicians spend less time adjusting and more time following a patient;
• Potential decrease in expenses of the operating room by 27% due to decrease in expenses on anesthetics thanks to reduction of waste of anesthetics.

Anesthesiologist and Director of Clinical Bioengineering at the Department of Anesthesiology Jim Filip described that we had previously continually adjusted evaporator settings and fresh gas flow to control the concentration of anesthetic in inhaled air, trying to achieve and maintain the final tidal concentration we wanted for our patients. Philip added that anesthesiologists in the United States will have access to the most modern anesthesia tools to improve patient care, and this technology allows direct control of the final tidal concentration, reflecting the level of the drug in the patient's blood.

Market entry was supported by the results of the US multi-center multi-year MASTER-Anesthesia trial, which involved more than 200 patients aged 18 years and older. The test evaluated the safety and reliability of Et Control compared to conventional anesthetic gas delivery methods during general anesthesia. After receiving approval, GE Healthcare will begin selling the Aisys CS2 anesthesia delivery system with the Et Control system in the United States around early June 2022.^[1]

Notes